Pasithea Therapeutics Corp.
corporate_fare Company Profile
Pasithea Therapeutics Corp. (NASDAQ:KTTA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for KTTA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 8/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for KTTA spans 4, 10-Q, 8-K, PRE 14A.
Recent high-impact activity:
- 10% Holder Coastlands Buys $806K of Pasithea Stock Over Three Sessions
- Pasithea Q3 Loss Widens to $6.6M as R&D Spend Triples; $41.2M Cash Remains
- PAS-004 Cuts Cutaneous Neurofibroma Size 41% in Phase 1/1b, Two Partial Responses in Plexiform Tumors
- FDA Clears IND for Pasithea's PAS-004 in Cutaneous Neurofibromas, Opening Second Phase 2 Path
- Pasithea to Unveil First PAS-004 NF1 Clinical Data at European Conference
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 386,722 shares in KTTA as of the October 30, 2026 settlement, a 121.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 38.6% of KTTA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.